Citations

Showing 10 of 108162 citations.

Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances
Maron, Bradley A. , Abman, Steven H. , Elliott, C. Gregory , Hopper, Rachel K. , Nicolls, Mark R. , Shlobin, Oksana A. , Kovács, Gábor , Olschewski, Horst , Olschewski, Horst , Frantz, Robert P. , Horn, Evelyn M. , Shah, Sanjiv J , Rosenzweig, Erika B.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | April 16, 2021 | Volume: 203 | Issue: 12 | Pages: 1472-1487

10.1164/rccm.202012-4317so | PMID 33861689 Get It

Abstract The diagnosis and management of pulmonary arterial hypertension (PAH) includes several advances, such as a broader recognition of extrapulmonary vascular organ system involvement, validated point-of-care clinical assessment tools, and focus on the early initiation of multiple pharmacotherapeutics in appropriate patients. Indeed, a principal goal in PAH today is an early diagnosis for prompt initiation of treatment to achieve a minimal symptom burden; optimize the patient’s biochemical, hemodynamic, and functional profile; and limit adverse events. To accomplish this end, clinicians must be familiar with novel risk factors and the revised hemodynamic definition for PAH. Fresh insights into the role of developmental biology (i.e., perinatal health) may also be useful for predicting incident PAH in early adulthood. Emergent or underused approaches to PAH management include a novel TGF-β ligand trap pharmacotherapy, remote pulmonary arterial pressure monitoring, next-generation imaging using inert gas–based magnetic resonance and other technologies, right atrial pacing, and pulmonary arterial denervation. These and other PAH state of the art advances are summarized here for the wider pulmonary medicine community.
Impact of COVID-19 Governmental Restrictions on Emergency General Surgery Operative Volume and Severity
Lund, Sarah , Fischmann, Marianna Martini , Maroun, Justin W. , Dang, Johnny , Markos, James , Zielinski, Martin D. , Stephens, Daniel , Stephens, Daniel , MacArthur, Taleen, Maroun, Justin, Markos, James R, Zielinski, Martin, MacArthur, Taleen A. , Markos, James R., Stephens, Daniel, Stephens, Daniel

Mayo Clinic

The American Surgeon™ | April 16, 2021 | Volume: 89 | Issue: 5 | Pages: 1457-1460

10.1177/00031348211011113 | PMID 33861672 Get It

Background To describe the effect of the COVID-19 pandemic on emergency general surgery operative volumes during governmental shutdowns secondary to the pandemic and characterize differences in disease severity, morbidity, and mortality during this time compared to previous years. Methods This retrospective cohort study compares patients who underwent emergency general surgery operations at a tertiary hospital from March 1st to May 31st of 2020 to 2019. Average emergent cases per day were analyzed, comparing identical date ranges between 2020 (pandemic group) and 2019 (control group). Secondary analysis was performed analyzing disease severity, morbidity, and mortality. Results From March 1st to May 31st, 2020, 2.5 emergency general surgery operations were performed on average daily compared to 3.0 operations on average daily in 2019, a significant decrease ( P = .03). No significant difference was found in presenting disease severity, morbidity, or mortality between the pandemic and control groups. Discussion This study demonstrates a decrease of 65% in emergency general surgery operations during governmental restrictions secondary to the COVID-19 pandemic. This decrease in operations was not associated with worse disease severity, morbidity, or mortality.
Microbiota restoration for recurrent Clostridioides difficile: Getting one step closer every day!
Khanna, Sahil , Khanna, S

Mayo Clinic

Journal of Internal Medicine | April 16, 2021 | Volume: 290 | Issue: 2 | Pages: 294-309

10.1111/joim.13290 | PMID 33856727 Get It

AbstractClostridioides difficile infection (CDI) is an urgent health threat being the most common healthcare‐associated infection, and its management is a clinical conundrum. Over 450 000 infections are seen in the United States with similar incidence seen in the rest of the developed world. The majority of infections seen are mild–moderate with fulminant disease and mortality being rare complications seen in the elderly and in those with comorbidities. The most common complication of CDI is recurrent infection with rates as high as 60% after three or more infections. A dilemma in the management of primary and recurrent CDI is testing due to the high sensitivity of the nucleic acid amplification tests such as the polymerase chain reaction, which leads to clinical false positives if patients are not chosen carefully (with symptoms) before testing. A newer testing regimen involving a 2‐step strategy is emerging using glutamate dehydrogenase as a screening strategy followed by enzyme immunoassay for the C. difficile toxin. Microbiota restoration therapies are the cornerstone of management of recurrent CDI to prevent future recurrences. The most common modality of microbiota restoration is faecal microbiota transplantation, which has been tainted with heterogeneity and adverse events such as serious infectious transmission. The success rates for recurrence prevention from microbiota restoration therapies are over 90% compared with less than 50% of recurrence prevention with courses of antibiotics. This has led to development and emergence of standardized microbiota restoration therapies in capsule and enema forms. Capsule‐based therapies include CP101 (positive phase II results), RBX7455 (positive phase I results), SER‐109 (positive phase III results) and VE303 (ongoing phase II trial). Enema‐based therapy includes RBX2660 (positive phase III data). This review summarizes the principles of management and diagnosis of CDI and focuses on emerging and existing data on faecal microbiota transplantation and standardized microbiota restoration therapies.
Sildenafil administration improves right ventricular function on 4D flow MRI in young adults born premature
Corrado, Philip A. , Barton, Gregory P. , Wieben, Oliver , François, Christopher J. , Goss, Kara N , Wieben, Oliver

Mayo Clinic

American Journal of Physiology-Heart and Circulatory Physiology | April 16, 2021 | Volume: 320 | Issue: 6 | Pages: H2295-H2304

10.1152/ajpheart.00824.2020 | PMID 33861148 Get It

We assessed the effect of right ventricular afterload reduction with sildenafil and heart rate reduction with metoprolol on cardiac hemodynamics and function in young adults born premature using 4D flow MRI. Metoprolol depressed cardiac function, whereas sildenafil improved cardiac function including right ventricular direct flow fraction by 4D flow, consistent with hemodynamic improvement. This suggests that the preterm heart is dependent on heart rate and sensitive to right ventricular afterload changes.Listen to this article's corresponding podcast at https://ajpheart.podbean.com/e/behind-the-bench-episode-9 .
Faculty Opinions recommendation of Effects of α-Synuclein-Associated Post-Translational Modifications in Parkinson's Disease.
Caviness, John N.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 16, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.739822004.793584332 Get It

Role of α2-Adrenoceptor Subtypes in Suppression of L-Type Ca2+ Current in Mouse Cardiac Myocytes
Evdokimovskii, Edward V., Jeon, Ryoung‐Hoon , Park, Sungjo , Pimenov, Oleg Y. , Alekseev, Alexey E., Jeon, Ryounghoon

Mayo Clinic

International Journal of Molecular Sciences | April 16, 2021 | Volume: 22 | Issue: 8 | Pages: 4135

10.3390/ijms22084135 | PMID 33923625 Get It

Sarcolemmal α2 adrenoceptors (α2-AR), represented by α2A, α2B and α2C isoforms, can safeguard cardiac muscle under sympathoadrenergic surge by governing Ca2+ handling and contractility of cardiomyocytes. Cardiomyocyte-specific targeting of α2-AR would provide cardiac muscle-delimited stress control and enhance the efficacy of cardiac malfunction treatments. However, little is known about the specific contribution of the α2-AR subtypes in modulating cardiomyocyte functions. Herein, we analyzed the expression profile of α2A, α2B and α2C subtypes in mouse ventricle and conducted electrophysiological antagonist assay evaluating the contribution of these isoforms to the suppression of L-type Ca2+ current (ICaL). Patch-clamp electro-pharmacological studies revealed that the α2-agonist-induced suppression of ICaL involves mainly the α2C, to a lesser extent the α2B, and not the α2A isoforms. RT-qPCR evaluation revealed the presence of adra2b and adra2c (α2B and α2C isoform genes, respectively), but was unable to identify the expression of adra2a (α2A isoform gene) in the mouse left ventricle. Immunoblotting confirmed the presence only of the α2B and the α2C proteins in this tissue. The identified α2-AR isoform-linked regulation of ICaL in the mouse ventricle provides an important molecular substrate for the cardioprotective targeting.
A brief overview of clinical significance of blood group antibodies
Strong, D.M., Whitaker, Barbee , Gandhi, Manish J. , Petrisli, Evangelia

Mayo Clinic

Immunohematology | April 16, 2021 | Volume: 34 | Issue: 1 | Pages: 4-6

10.21307/immunohematology-2018-002 Get It

Abstract This review was derived from a presentation made on September 2, 2016 for the first Academy Day presented by the Working Party on Immunohematology at the International Society of Blood Transfusion (ISBT) Congress in Dubai. The focus of this review is to provide a brief overview of the clinical significance of blood group antibodies. Blood group antibodies can be naturally occurring (e.g., anti-A and anti-B through exposure to naturally occurring red blood cell [RBC] antigen-like substances) or can occur via exposure to foreign (donor) RBC antigens through previous transfusions, transplants, or exposure to fetal RBCs during or after pregnancy. However, not all blood group antibodies are clinically significant. Clinically significant blood group antibodies can cause adverse events after blood component transfusion or transplantation and/or can cause hemolytic disease of the fetus and newborn. Immunohematology 2018;34:4–6.
Patient-reported outcome improvements at 24-month follow-up after fusion added to decompression for grade I degenerative lumbar spondylolisthesis: a multicenter study using the Quality Outcomes Database
Bisson, Erica F. , Bydon, Mohamad , Alvi, Mohammed Ali , Glassman, Steven D. , Foley, Kevin T. , Potts, Eric A. , Shaffrey, Christopher I. , Shaffrey, Mark E., Coric, Domagoj , Knightly, John J. , Park, Paul , Wang, Michael Y. , Fu, Kai-Ming, Slotkin, Jonathan R., Asher, Anthony L. , Virk, Michael S. , Yew, Andrew, Haid, Regis W., Chan, Andrew K. , Mummaneni, Praveen V. , Alvi, Mohammed A, Alvi, Mohammed Ali , Guan, Jian , Goyal, Anshit

Mayo Clinic

Journal of Neurosurgery: Spine | April 16, 2021 | Volume: 35 | Issue: 1 | Pages: 42-51

10.3171/2020.9.spine201082 | PMID 33862593 Get It

OBJECTIVE The ideal surgical management of grade I lumbar spondylolisthesis has not been determined despite extensive prior investigations. In this cohort study, the authors used data from the large, multicenter, prospectively collected Quality Outcomes Database to bridge the gap between the findings in previous randomized trials and those in a more heterogeneous population treated in a typical practice. The objective was to assess the difference in patient-reported outcomes among patients undergoing decompression alone or decompression plus fusion. METHODS The primary outcome measure was change in 24-month Oswestry Disability Index (ODI) scores. The minimal clinically important difference (MCID) in ODI score change and 30% change in ODI score at 24 months were also evaluated. After adjusting for patient-specific and clinical factors, multivariable linear and logistic regressions were employed to evaluate the impact of fusion on outcomes. To account for differences in age, sex, body mass index, and baseline listhesis, a sensitivity analysis was performed using propensity score analysis to match patients undergoing decompression only with those undergoing decompression and fusion. RESULTS In total, 608 patients who had grade I lumbar spondylolisthesis were identified (85.5% with at least 24 months of follow-up); 140 (23.0%) underwent decompression alone and 468 (77.0%) underwent decompression and fusion. The 24-month change in ODI score was significantly greater in the fusion plus decompression group than in the decompression-only group (−25.8 ± 20.0 vs −15.2 ± 19.8, p < 0.001). Fusion remained independently associated with 24-month ODI score change (B = −7.05, 95% CI −10.70 to −3.39, p ≤ 0.001) in multivariable regression analysis, as well as with achieving the MCID for the ODI score (OR 1.767, 95% CI 1.058–2.944, p = 0.029) and 30% change in ODI score (OR 2.371, 95% CI 1.286–4.371, p = 0.005). Propensity score analysis resulted in 94 patients in the decompression-only group matched 1 to 1 with 94 patients in the fusion group. The addition of fusion to decompression remained a significant predictor of 24-month change in the ODI score (B = 2.796, 95% CI 2.228–13.275, p = 0.006) and of achieving the 24-month MCID ODI score (OR 2.898, 95% CI 1.214–6.914, p = 0.016) and 24-month 30% change in ODI score (OR 2.300, 95% CI 1.014–5.216, p = 0.046). CONCLUSIONS These results suggest that decompression plus fusion in patients with grade I lumbar spondylolisthesis may be associated with superior outcomes at 24 months compared with decompression alone, both in reduction of disability and in achieving clinically meaningful improvement. Longer-term follow-up is warranted to assess whether this effect is sustained.
Selection of Mediastinal Lymphoma Patients for Proton Therapy Within the Proton Collaborative Group Registry
Pankuch, Mark , McGee, L.A. , Rossi, Carl J., Flampouri, Stella , Hajj, Carla , Molitoris, Jason K. , Chang, John, Stevens, Craig , Rosen, L, Vargas, Carlos , Hartsell, William F. , McGee, Lisa, Tseng, Yolanda D. , Mohindra, Pranshu , Tsai, Henry K.

Mayo Clinic

American Journal of Clinical Oncology | April 16, 2021 | Volume: 44 | Issue: 6 | Pages: 269-274

10.1097/coc.0000000000000819 | PMID 33852456 Get It

Purpose: As patients with mediastinal lymphoma are typically young with curable disease, advanced radiation techniques such as proton therapy are often considered to minimize subacute and late toxicity. However, it is unclear which mediastinal lymphoma patients are treated with proton therapy. Within a prospective, multi-institutional proton registry, we characterized mediastinal lymphoma patients treated with proton therapy and assessed concordance with consensus recommendations published in 2018 by the International Lymphoma Radiation Oncology Group (ILROG). Methods: Eligible patients included those with lymphoma of the mediastinum treated exclusively with proton therapy for whom digital imaging and communications in medicine (DICOM) treatment data were available for review. Given the challenge with reliably visualizing the left mainstem coronary artery, the inferior-most aspect of the left pulmonary artery (PA) was used as a surrogate. Extent of disease was characterized as upper mediastinum (above level of left PA), middle mediastinum (below left PA but at or above level of T8), or low mediastinum (below T8). Results: Between November 2012 and April 2019, 56 patients were treated and met inclusion criteria. Patients treated with proton therapy were young (median, 24 y; range: 12 to 88), with over half being female (55%). Patients were most commonly treated at initial diagnosis (86%) and had Hodgkin lymphoma (79%). Most patients (96%) had mediastinal disease that extended down to the level of the heart: 48% had middle and 48% had low mediastinal involvement. Nearly all patients (96%) met the ILROG consensus recommendations: 95% had lower mediastinal disease, 46% were young females, and 9% were heavily pretreated. Heart (mean) and lung dose (mean, V5, V20) were significantly associated with lowest extent of mediastinal disease. Conclusions: Mediastinal lymphoma patients treated with proton therapy are typically young with lower mediastinal involvement. Within a prospective, multi-institutional proton registry, nearly all treated patients fit the ILROG consensus recommendations regarding which mediastinal lymphoma patients may most benefit from proton therapy.
Speech Biomarkers in Rapid Eye Movement Sleep Behavior Disorder and Parkinson Disease
Rusz, Jan , Hlavnička, Jan , Novotný, Michal , Pelletier, Amélie , Montplaisir, Jacques , Gagnon, Jean‐François , Dušek, Petr , Galbiati, Andrea , Timm, Paul, Teigen, Luke, Janzen, Annette , Habibi, Mahboubeh , Stefani, Ambra , Holzknecht, Evi , Evangelista, Elisa , Rassu, Anna Laura, Oertel, Wolfgang H. , Louis, Erik K. St. , Dušek, Petr , Galbiati, Andrea , Timm, Paul C, Teigen, Luke N, Dauvilliers, Yves , St Louis, E K , Ferini-Strambi, Luigi , Postuma, Ronald B , Stefani, Ambra , Rusz, Jan , Tykalová, Tereza , Marelli, Sara , Seppi, Klaus , Dauvilliers, Yves , Högl, Birgit , Růžička, Evžen , Postuma, Ronald B. , Šonka, Karel

Mayo Clinic

Annals of Neurology | April 16, 2021 | Volume: 90 | Issue: 1 | Pages: 62-75

10.1002/ana.26085 | PMID 33856074 Get It

ObjectiveThis multilanguage study used simple speech recording and high‐end pattern analysis to provide sensitive and reliable noninvasive biomarkers of prodromal versus manifest α‐synucleinopathy in patients with idiopathic rapid eye movement sleep behavior disorder (iRBD) and early‐stage Parkinson disease (PD).MethodsWe performed a multicenter study across the Czech, English, German, French, and Italian languages at 7 centers in Europe and North America. A total of 448 participants (337 males), including 150 with iRBD (mean duration of iRBD across language groups 0.5–3.4 years), 149 with PD (mean duration of disease across language groups 1.7–2.5 years), and 149 healthy controls were recorded; 350 of the participants completed the 12‐month follow‐up. We developed a fully automated acoustic quantitative assessment approach for the 7 distinctive patterns of hypokinetic dysarthria.ResultsNo differences in language that impacted clinical parkinsonian phenotypes were found. Compared with the controls, we found significant abnormalities of an overall acoustic speech severity measure via composite dysarthria index for both iRBD (p = 0.002) and PD (p < 0.001). However, only PD (p < 0.001) was perceptually distinct in a blinded subjective analysis. We found significant group differences between PD and controls for monopitch (p < 0.001), prolonged pauses (p < 0.001), and imprecise consonants (p = 0.03); only monopitch was able to differentiate iRBD patients from controls (p = 0.004). At the 12‐month follow‐up, a slight progression of overall acoustic speech impairment was noted for the iRBD (p = 0.04) and PD (p = 0.03) groups.InterpretationAutomated speech analysis might provide a useful additional biomarker of parkinsonism for the assessment of disease progression and therapeutic interventions. ANN NEUROL 2021;90:62–75